Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 2/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | YES1 | P07947 | 1/20 | 0.33 |
| ▸ | LYN | P07948 | 1/20 | 0.33 |
| ▸ | FGR | P09769 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2911364 | 0.91 | SIGMAR1 (0.35) | PIM1SIGMAR1HRH3 | |
| SCHEMBL666678 | 0.86 | ALOX15 (0.45) | PIM1ALOX15KDM4EALDH1A1LMNA | |
| SCHEMBL2231151 | 0.84 | PIM1 (0.42) | PIM1ALOX15KDM4EALDH1A1LMNA | |
| SCHEMBL1186740 | 0.84 | — | — | |
| SCHEMBL42161 | 0.79 | SIGMAR1 (0.36) | SIGMAR1 | |
| SCHEMBL9927905 | 0.79 | — | — | |
| SCHEMBL3671614 | 0.79 | SIGMAR1 (0.46) | SIGMAR1HRH3 | |
| SCHEMBL41978 | 0.78 | SIGMAR1 (0.41) | SIGMAR1HRH3 | |
| SCHEMBL42491 | 0.78 | MEN1 (0.34) | ACHE | |
| SCHEMBL24891389 | 0.77 | HRH3 (0.48) | SIGMAR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2058302-B1 | METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2013-04-17 | — | — | EP | claimed |
| EP-2301928-A1 | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders | AstraZeneca AB (SE) | 2011-03-30 | — | — | EP | claimed |
| US-7790885-B2 | Process for preparing phenoxypyridine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-09-07 | — | — | US | claimed |
| EP-2010496-B1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-08-25 | — | — | EP | claimed |
| US-20090163515-A1 | Compounds Which Bind to the Active Site of Protein Kinase Enzymes | BIOFOCUS DISCOVERY LTD. | 2009-06-25 | — | — | US | claimed |
| EP-2058302-A1 | METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2009-05-13 | — | — | EP | claimed |
| US-7528162-B2 | 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS, B.V. (NL) | 2009-05-05 | — | — | US | claimed |
| US-20090054411-A1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | claimed |
| EP-2010496-A1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | claimed |
| US-20080280906-A1 | Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | claimed |
| WO-2006072792-A2 | COMPOUNDS WHICH BIND TO THE ACTIVE SITE OF PROTEIN KINASE ENZYMES | GALAPAGOS NV (BE) | 2006-07-13 | — | — | WO | claimed |
| EP-1644365-A2 | PYRAZINE AND PYRIDINE DERIVATIVES AS RHO KINASE INHIBITORS | Biofocus Discovery Ltd (GB) | 2006-04-12 | — | — | EP | claimed |
| WO-2005003101-A2 | PYRAZINE AND PYRIDINE DERIVATIVES AS RHO KINASE INHIBITORS | BIOFOCUS DISCOVERY LIMITED (GB) | 2005-01-13 | — | — | WO | claimed |
| US-20030008863-A1 | Novel tricyclic diazepines tocolytic oxytocin receptor antagonists | WYETH | 2003-01-09 | — | — | US | claimed |
| EP-0614664-B2 | Quinolonecarboxylic acid derivatives, their preparation and their use as cell adhesion inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-01-08 | — | — | EP | claimed |
| WO-2002064558-A2 | OXAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS CYTOKINE INHIBITORS | SANKYO COMPANY, LIMITED (JP) | 2002-08-22 | — | — | WO | claimed |
| EP-0614664-B1 | Quinolonecarboxylic acid derivatives, their preparation and their use as cell adhesion inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-09-16 | — | — | EP | claimed |
| US-5705662-A | HYPOTENSIVE AGENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1998-01-06 | — | — | US | claimed |
| US-4818748-A | HYPOTENSIVE AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1989-04-04 | — | — | US | claimed |
| EP-0236874-A2 | Renin inhibitors, their production and use, as well as derivatives of amino acids and amino aldehydes | BAYER AG (DE) | 1987-09-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163515-A1 | Compounds Which Bind to the Active Site of Protein Kinase Enzymes | ROCK1, ROCK2, CIT | PIM1 653/4885FYN 114/4885YES1 111/4885 |
| US-20030008863-A1 | Novel tricyclic diazepines tocolytic oxytocin receptor antagonists | OXTR, OPRL1, HCRTR2 | PIM1 4711/4885FYN 2983/4885YES1 4838/4885 |
| US-20080280906-A1 | Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders | CCNI, MKI67, TYMP | PIM1 1122/4885FYN 2618/4885YES1 1641/4885 |
| US-20090054411-A1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | CSF1R, CSF3R, FLT3 | PIM1 363/4885FYN 305/4885YES1 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.